Chitosan coating of anionic liposomes containing sumatriptan succinate: a candidate for nasal administration

IF 1.4 Q4 NANOSCIENCE & NANOTECHNOLOGY
S. Assadpour, M. Shiran, J. Akhtari
{"title":"Chitosan coating of anionic liposomes containing sumatriptan succinate: a candidate for nasal administration","authors":"S. Assadpour, M. Shiran, J. Akhtari","doi":"10.22038/NMJ.2021.08.006","DOIUrl":null,"url":null,"abstract":"Objective(s): Sumatriptan is a routine medication in the treatment of migraine and cluster headache that is generally given by oral or parental routes. However, a substantial proportion of patients suffer severe side effects. Nasal administration is significantly effective in case of oral administration of drug gives an undesirable side effect. So, the purpose of the present study was to develop intranasal delivery systems of Sumatriptan succinate using nanoliposomes as container of a water-soluble drug and chitosan as a mucoadhesive polymer.Materials and Methods: Liposomal formulations containing Sumatriptan as well as chitosan-coated liposomal formulations with different phospholipids and different concentrations were prepared. The formulations were evaluated for their physicochemical properties, stability and Cytotoxicity on BEAS-2B cells.Results: The prepared liposomal formulations coated with chitosan containing Sumatriptan had a size range of 165±9.4to 258±6.4 nm, and the surface charge of the obtained formulations was measured between 32±6 and 40±5 mV. Also, the encapsulation efficiency of the formulations was also observed between 14.2±2.7% and 19±3.4%. Based on the obtained results of physicochemical studies, liposomes F2 was also tested for stability and toxicity and showed that the F2 liposomes retained its physicochemical properties for up to 3 months. Finally, the toxicity test of the mentioned formulation showed relatively low toxicity on BEAS-2B cells.Conclusion: In the presents study, stable liposomal formulations coated with chitosan containing Sumatriptan were prepared and studied. Based on the obtained, these formulations can be used in preclinical and animal studies for the nasal administration of Sumatriptan.","PeriodicalId":18933,"journal":{"name":"Nanomedicine Journal","volume":"8 1","pages":"132-139"},"PeriodicalIF":1.4000,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22038/NMJ.2021.08.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NANOSCIENCE & NANOTECHNOLOGY","Score":null,"Total":0}
引用次数: 5

Abstract

Objective(s): Sumatriptan is a routine medication in the treatment of migraine and cluster headache that is generally given by oral or parental routes. However, a substantial proportion of patients suffer severe side effects. Nasal administration is significantly effective in case of oral administration of drug gives an undesirable side effect. So, the purpose of the present study was to develop intranasal delivery systems of Sumatriptan succinate using nanoliposomes as container of a water-soluble drug and chitosan as a mucoadhesive polymer.Materials and Methods: Liposomal formulations containing Sumatriptan as well as chitosan-coated liposomal formulations with different phospholipids and different concentrations were prepared. The formulations were evaluated for their physicochemical properties, stability and Cytotoxicity on BEAS-2B cells.Results: The prepared liposomal formulations coated with chitosan containing Sumatriptan had a size range of 165±9.4to 258±6.4 nm, and the surface charge of the obtained formulations was measured between 32±6 and 40±5 mV. Also, the encapsulation efficiency of the formulations was also observed between 14.2±2.7% and 19±3.4%. Based on the obtained results of physicochemical studies, liposomes F2 was also tested for stability and toxicity and showed that the F2 liposomes retained its physicochemical properties for up to 3 months. Finally, the toxicity test of the mentioned formulation showed relatively low toxicity on BEAS-2B cells.Conclusion: In the presents study, stable liposomal formulations coated with chitosan containing Sumatriptan were prepared and studied. Based on the obtained, these formulations can be used in preclinical and animal studies for the nasal administration of Sumatriptan.
壳聚糖包覆琥珀酸酯舒马曲坦阴离子脂质体:鼻腔给药的候选药物
目的:舒马曲坦是治疗偏头痛和丛集性头痛的常规药物,通常通过口服或父母途径给予。然而,相当一部分患者会遭受严重的副作用。在口服药物产生不良副作用的情况下,鼻腔给药是非常有效的。因此,本研究的目的是利用纳米脂质体作为水溶性药物的容器,壳聚糖作为黏附聚合物,开发琥珀酸舒马曲坦的鼻内给药系统。材料与方法:制备了含苏马曲坦的脂质体制剂和不同磷脂、不同浓度的壳聚糖包被脂质体制剂。对其理化性质、稳定性和对BEAS-2B细胞的细胞毒性进行了评价。结果:制备的苏马曲坦壳聚糖包被脂质体的粒径范围为165±9.4 ~ 258±6.4 nm,表面电荷在32±6 ~ 40±5 mV之间。包封率在14.2±2.7% ~ 19±3.4%之间。根据获得的理化研究结果,对脂质体F2进行了稳定性和毒性测试,结果表明F2脂质体的理化性质可保持3个月。最后,上述配方的毒性试验显示对BEAS-2B细胞的毒性较低。结论:制备并研究了含苏马曲坦壳聚糖包被的稳定脂质体。根据所获得的结果,这些制剂可用于舒马曲坦鼻给药的临床前和动物研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nanomedicine Journal
Nanomedicine Journal NANOSCIENCE & NANOTECHNOLOGY-
CiteScore
3.40
自引率
0.00%
发文量
0
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信